Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data
نویسندگان
چکیده
منابع مشابه
Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor
We herein present the case of a 21-year-old diabetic obese woman who developed ketoacidosis following the administration of ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. At the time of admission, although her serum glucose level was only 175 mg/dL, laboratory tests showed ketoacidosis. Interestingly, hyperglycosuria persisted, even after the discontinuation of ipragliflozin...
متن کاملOBSERVATIONS Diabetic Ketoacidosis Associated With Orlistat Treatment
O rlistat is a drug frequently prescribed as an adjuvant in weight control therapy (1–2). Orlistat inhibits gastric and pancreatic lipases in the lumen of the gastrointestinal tract to decrease the systemic absorption of dietary fat (1,2). In clinical trials, steatorrhoea and other gastrointestinal disorders are the most frequently reported side effects (3). Other reported adverse effects inclu...
متن کاملTreatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication
BACKGROUND The second-generation antipsychotics (SGAs) are associated with metabolic disturbances. Diabetic ketoacidosis (DKA) is a rare, but potentially fatal sign of acute glucose metabolism dysregulation, which may be associated with the use of SGAs. This study aims to review published reports of patients with schizophrenia and antipsychotic drug-associated DKA, focusing on the effective man...
متن کاملEuglycemic Diabetic Ketoacidosis in a Patient with Type II Diabetes Mellitus, Ascites and Poor Nutrition on SGLT2 Inhibitor
Title: This is the case of a patient with Euglycemic Diabetic Ketoacidosis (euDKA), ascites, poor nutrition and diabetes mellitus type II on SGLT2 inhibitor. Background: euDKA is an under-reported and under-diagnosed condition that mainly occurs in type I diabetes mellitus patients and in patients with prolonged starvation. The aim of this report is to shed the light on an additional risk facto...
متن کاملNovel SGLT2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected renal effects
The antisense compound ISIS 388626 selectively inhibits renal glucose reabsorption by inhibiting the sodium-glucose cotransporter-2 (SGLT2) mRNA expression. It is developed as an insulin-independent treatment approach for type 2 diabetes mellitus (T2DM). The safety, tolerability, pharmacokinetics, and pharmacodynamics after subcutaneous administration of the drug were planned to be evaluated in...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes/Metabolism Research and Reviews
سال: 2017
ISSN: 1520-7552
DOI: 10.1002/dmrr.2924